USANA Health Sciences, Inc. $USNA Stock Sold by Pzena Investment Management LLC

Posted by Brenda Bartman on Nov 6th, 2026

Pzena Investment Management LLC trimmed its holdings in shares of USANA Health Sciences, Inc. (NYSE:USNA – Free Report) by 7.6% in the third quarter, Holdings Channel.com reports. The firm owned 1,113,983 shares of the company’s stock after selling 91,604 shares during the quarter. Pzena Investment Management LLC owned approximately 0.06% of USANA Health Sciences worth $16,119,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in USANA Health Sciences in the 2nd quarter valued at $33,182,000. Empowered Funds LLC acquired a new position in shares of USANA Health Sciences during the 2nd quarter worth about $1,500,000. Nantahala Capital Management LLC bought a new position in USANA Health Sciences in the second quarter valued at approximately $17,295,080. Bank of New York Mellon Corp bought a new position in shares of USANA Health Sciences in the second quarter valued at $1,105,000. Finally, Lazard Asset Management LLC acquired a new position in shares of USANA Health Sciences during the 1st quarter worth about $1,265,000. 54.25% of the stock is currently owned by institutional investors and hedge funds.

USANA Health Sciences Stock Down 3.3%

Shares of NYSE:USNA opened at $13.86 on Friday. USANA Health Sciences, Inc. has a 12-month low of $12.57 and a 12-month high of $23.59. The stock has a market cap of $256.05 million, a PE ratio of -12.05, a P/E/G ratio of 2.17 and a beta of 0.66. The business has a 50 day moving average of $14.61 and a 200-day moving average of $17.99.

USANA Health Sciences (NYSE:USNA – Get Free Report) last announced its earnings results on Tuesday, November 3rd. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.22). The firm had revenue of $205.89 million for the quarter, compared to the consensus estimate of $217.42 million. USANA Health Sciences had a positive return on equity of 3.56% and a negative net margin of 2.34%. Equities research analysts expect that USANA Health Sciences, Inc. will post 0.55 earnings per share for the current year.

Key USANA Health Sciences News

Here are the key news stories impacting USANA Health Sciences this week:

Positive Sentiment: Sidoti slightly raised its Q4 2026 EPS estimate to $0.12 from $0.11, a modest offset to its broader forecast reductions. USANA analyst estimates
Negative Sentiment: USANA’s Q3 2026 results missed expectations: the company reported a loss of $0.11 per share versus consensus earnings of $0.11, while revenue of $205.9 million fell short of the $217.4 million estimate. Sales declined 4% year over year. USANA Q3 results and outlook
Negative Sentiment: The company lowered its FY2026 outlook, now projecting net sales approaching $900 million and adjusted EBITDA of approximately $77 million. The reduced guidance suggests weaker near-term business performance. USANA updates its outlook
Negative Sentiment: Sidoti lowered its FY2027 EPS forecast to $1.59 from $1.77 and cut estimates for Q1, Q2, and Q3 2027, indicating less confidence in earnings growth beyond 2026. USANA analyst estimates

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Zacks Research upgraded shares of USANA Health Sciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 5th. Wall Street Zen downgraded USANA Health Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a research note on Monday, September 21st. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, USANA Health Sciences currently has a consensus rating of “Reduce”.

View Our Latest Stock Report on USNA

USANA Health Sciences Company Profile

(Free Report)

USANA Health Sciences, Inc develops and sells nutritional supplements, healthy foods and personal-care products through a direct-selling business model. Its product portfolio includes vitamins and mineral supplements, meal-replacement and snack products, sports nutrition offerings, and skincare products marketed under the USANA and related brands.

Founded in 1992 by microbiologist and immunologist Myron W. Wentz, the company is headquartered in Salt Lake City, Utah. USANA distributes its products through a network of independent associates and preferred customers rather than primarily through traditional retail channels.

The company serves customers in markets across the Americas, Asia-Pacific and Europe, with a significant presence in countries including the United States, Canada, Australia, New Zealand, China, Hong Kong, Japan, South Korea, the Philippines, Singapore, Malaysia and Thailand.